Dublin, May 06, 2025 (GLOBE NEWSWIRE) -- The "Bioconjugation Market Size, Share & Trends Analysis Report By Product & Services (Consumables, Instruments, Services), By Technique, By Biomolecule Type, ...

Bioconjugation involves the covalent linkage of drugs or drug carriers to biological macromolecules, thereby enhancing their stability, solubility, and pharmacokinetics. This conjugation strategy ...

Bioconjugation is the process of chemically joining two or more molecules by a covalent bond, where at least one molecule is a biomolecule. The attachment of various chemical groups to proteins or ...

Lonza plans to increase bioconjugation capacity for the production of antibody drug conjugates (ADCs) by 300% with the addition of two commercial-scale bioconjugation suites at its manufacturing site ...

STAAD, Switzerland--(BUSINESS WIRE)--Biosynth, a supplier of critical raw materials to the life science industry, is pleased to announce today that it has acquired celares, a leader in the development ...

Officials at Lonza say they will invest in additional bioconjugation capabilities in Visp, Switzerland. The expansion will add two multipurpose 1,200L manufacturing suites and manufacturing-related ...

The new suite extends GMP bioconjugate production for intermediates and active pharmaceutical ingredients from early clinical phase through to late clinical phases and commercial supply. STAAD, ...

Bioconjugation is the chemical linking of two biomolecules to form a single hybrid that retains the biological activity of each component, yet provides a novel function that is not possible with each ...

Unlike current approaches where bioconjugation is typically done following the manufacture of the monoclonal antibody and the cytotoxic drug, the new method begins with the antibody supernatants and ...

Biomacromolecules, including proteins, enzymes, and antibodies, are the workhorses of living systems and the foundation of breakthrough technologies in medicine, energy, sustainability, and food ...

Syngene International, a global contract research, development and manufacturing organization (CRDMO), is adding a GMP bioconjugation suite at its commercial biologics facility [Unit 3] in Bengaluru.